{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-25-000074","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.891780+00:00","generated_at":"2026-05-21T22:37:45.197339+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Exelixis Q1 2025: Revenue $555.4M, GAAP EPS $0.55; raises FY2025 guidance by $100M","bullets":["Total revenues $555.4M (up 31% YoY); Cabozantinib U.S. net product revenues $513.3M (up 36% YoY).","GAAP diluted EPS $0.55 vs $0.12 in Q1 2024; Non-GAAP diluted EPS $0.62 vs $0.17.","Increasing 2025 full year net product revenues and total revenues guidance by $100M.","CABOMETYX launched in advanced NET after March FDA approval; initial reception positive.","Pipeline milestones: zanzalintinib pivotal readouts in CRC, nccRCC expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-25-000074","json":"https://secwatch.observer/filing/0000939767-25-000074.json","markdown":"https://secwatch.observer/filing/0000939767-25-000074.md","text":"https://secwatch.observer/filing/0000939767-25-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000074/0000939767-25-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000074/exel-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T22:37:45.197339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}